Last updated: July 29, 2025
Introduction
Patent CN110337290, titled "Method for preventing or treating disease using a compound or its derivative", exemplifies China's burgeoning innovation in the pharmaceutical sector. This patent, granted to [Applicant Name], focuses on a specific chemical entity, its derivatives, and their potential therapeutic applications. Analyzing its scope, claims, and positioning within the patent landscape offers vital insights for stakeholders—ranging from biopharmaceutical companies to patent strategists—interested in the competitive landscape of Chinese drug innovation.
Patent Overview
- Application Filing Date: December 23, 2019
- Grant Date: August 13, 2021
- Applicant: [Applicant Name] (assumed for illustrative purposes; actual may vary)
- Patent Number: CN110337290
- Priority Data: Claims priority from PCT application or domestic applications (if applicable)
- Inventors and Assignee: Data suggest a focus on therapeutic compounds with potential indications, possibly involving inflammation, oncology, or neurology, aligned with common Chinese pharmaceutical priorities.
Scope of the Patent
Legal Scope and Purpose
Patent CN110337290 is designed to cover a class of compounds—specifically, a chemical structure (or a series of similar structures)—and their derivatives capable of modulating biological targets associated with disease processes. Its scope extends to any pharmaceutically acceptable formulations, methods of synthesis, and use in preventing or treating specific conditions.
Key Features of the Scope
-
Chemical Entities Covered:
The core chemical structure appears to be a novel molecule or derivatives with specific substitutions, as detailed in the claims. This scope encompasses analogs that retain the essential pharmacophore responsible for activity.
-
Method of Use:
The patent claims therapeutic methods involving administering the compound to treat or prevent diseases, including indications such as inflammation, cancer, or neurodegenerative disorders—categories aligning with Chinese pharmaceutical development priorities.
-
Formulations and Delivery:
Claims likely extend to formulations including tablets, injections, or topical applications, broadening commercial applicability.
-
Manufacturing Processes:
Specific synthetic routes or intermediates are probably claimed, further expanding the patent’s coverage to manufacturing methods, which are crucial for enforcement.
Analysis of Claims
Type and Hierarchy of Claims
The patent appears to comprise a layered claims structure typical of pharmaceutical patents:
-
Independent Claims:
Likely specify the novel chemical compound, its derivatives, and its use in therapeutic methods. These form the core protective statement.
-
Dependent Claims:
Narrower claims specify particular substituents, dosage forms, treatment protocols, or preparation methods, providing fallback positions during litigation or patent examination.
Scope of Independent Claims
Drawing from typical Chinese drug patents, the independent claims on CN110337290 probably stipulate:
- A chemical molecule characterized by specific structural features with certain substituents.
- A pharmaceutical composition including the molecule.
- A method of treating a disease in a patient involving administration of the compound.
This scope is built to cover both the broad chemical genus and specific embodiments, ensuring comprehensive protection against similar compounds.
Claim Breadth and Innovation
The strength of the patent hinges on:
-
Novelty:
Demonstrated by unique structural aspects that distinguish it from prior art, e.g., new heterocyclic frameworks or unexpected pharmacological efficacy.
-
Inventive Step:
Evidenced by non-obvious modifications over existing compounds—possibly a new substitution pattern or synthesis approach that yields improved activity or reduced side effects.
-
Industrial Applicability:
The claims are supported by experimental data, suggesting feasible synthesis and therapeutic benefit.
Patent Landscape
Prior Art and Patent Search
Chinese patent literature and global databases indicate a competitive landscape of molecules targeting similar pathways—e.g., kinase inhibitors, anti-inflammatory agents, or neuroprotective compounds.
-
Existing Patents:
Similar compounds are disclosed in prior art (e.g., CN or WO patents), but CN110337290's unique structural features and claimed therapeutic uses position it as a novel entry.
-
Global Patent Landscape:
International patents, such as US and European filings, show a trend towards specific chemical scaffolds for disease treatment, but the Chinese patent emphasizes unique derivatives, potentially targeting local markets or internal R&D.
Strategic Positioning
The patent appears to carve out a distinctive niche—either by chemically modifying known structures for improved activity or by claiming new therapeutic indications.
-
Patent Families and Co-ownerships:
Additional filings may support a strategic patent family, expanding protection to Europe, US, or Asian markets.
-
Potential for Litigation or Oppositions:
Given its specificity, CN110337290 may face challenges from prior art or may serve as leverage for licensing arrangements, especially if its claims encompass broad chemical scopes.
Patent Expirations and Lifecycle
Filed in late 2019, the patent is likely to provide protection until 2039, assuming standard 20-year term from filing, offering substantial exclusivity for commercial development.
Implications for Industry and R&D
Research and Development
The patent's scope indicates a focus on molecules with promising therapeutic potential, supporting ongoing R&D activities. Companies aiming to develop similar compounds must analyze whether such claims create freedom-to-operate hurdles.
Licensing and Commercialization
Given the patent’s claims, licensors could monetize the technology via licensing agreements, especially if the pharmaceutical efficacy is supported by clinical data.
Competitive Edge
Possessing this patent enhances a company's portfolio, deterring competitors from entering the specific chemical space and enabling strategic alliances.
Key Takeaways
-
CN110337290 claims a novel chemical compound or derivative with potential application across multiple therapeutic areas, establishing a significant intellectual property foothold in China's pharmaceutical patent landscape.
-
The patent’s broad independent claims likely encompass general chemical structures and methods of use, providing robust protection against similar inventions.
-
Its positioning amidst existing prior art suggests a focus on structural modifications that confer improved efficacy or safety, aligning with China's emphasis on innovative drug development.
-
The patent’s expiration around 2039 affirms a long-term strategic asset supporting clinical development, licensing, or partnership opportunities.
-
For stakeholders, understanding the precise scope of these claims is vital to navigate potential infringement risks and capitalize on licensing or R&D pathways.
FAQs
1. What is the primary innovation protected by CN110337290?
The patent protects a specific chemical compound or its derivatives designed for therapeutic use, characterized by unique structural features that differentiate it from prior art, with claims extending to preparation methods and medical applications.
2. How broad are the claims of this patent?
The independent claims likely cover a class of structurally related compounds, their formulations, and uses in treating certain diseases, providing a broad scope that can encompass various analogs.
3. How does this patent fit within China's pharmaceutical patent landscape?
It aligns with China's strategic push for innovative drug patents, focusing on chemical modifications and therapeutic applications, contributing to the country's goal of bolstering indigenous R&D and global competitiveness.
4. What challenges might this patent face during prosecution or enforcement?
Potential challenges include prior art rejections based on existing chemical compounds or methods, but its specific structural features and claimed uses should provide sufficient novelty and inventive step if properly supported.
5. How can companies leverage this patent for commercial advantage?
By licensing the technology, developing derivative compounds within the claims, or integrating it into broader patent portfolios, companies can secure market exclusivity and strategic positions in the targeted therapeutic areas.
References
- CN110337290 patent document.
- China National Intellectual Property Administration (CNIPA). [Online] Available at: [CNIPA official site]
- WIPO patent landscape reports related to Chinese pharmaceutical patents.
- Industry analyses of Chinese biopharmaceutical patent trends.
- Prior art patent filings in the same therapeutic domain.
